Drug Channels delivers timely analysis and provocative opinions from Adam J. Fein, Ph.D., the country's foremost expert on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 50,000 subscribers and followers. Learn more...

Tuesday, October 04, 2022

Five Surprising Facts About GoodRx and the Discount Card Market

Last month, IQVIA quietly released a fascinating new report on discount cards. (Link below.) The research was sponsored by the Association for Accessible Medicines (AAM).

Below, I highlight three unexpected findings from the data regarding GoodRx’s market position, when people use discount cards, how much they save, and why PBMs should still be worried about this market.

There’s a lot to unpack about the growing discount card market. As you’ll see, this report provides valuable insights about a market that seems stacked against patients.

Friday, September 30, 2022

Building New Data Connections Helps Brands Lower Adherence Barriers

Today’s guest post comes from Kylie Hall, Director of Product Management at ConnectiveRx.

Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence.

Click here to learn about the ConnectiveRx Enterprise Data Platform.

Read on for Kylie’s insights.

Tuesday, September 27, 2022

Drug Channels News Roundup, September 2022: Patients vs. SaveonSP, PBMs’ Oncology Exclusions, Medicare Advantage Winners, HRSA’s 340B Reveal, and New DCI Offerings

Autumn is here! Please savor these Drug Channels acorns that we’ve squirrelled away for you:
  • One patient’s troubling experience with SaveonSP
  • PBMs ramp up formulary exclusions for oncology drugs
  • The mega-players dominating Medicare Advantage
  • My 340B FOIA efforts yield change at HRSA!
Plus, two new resources from Drug Channels Institute.

P.S. Join my 32,000 LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 15,200 followers.

Friday, September 23, 2022

Managing 340B, Medicaid Drug Discounts: Technology for Collaboration – Anywhere, Anytime

Today’s guest post comes from Lindsey Alves, Vice President of Customer Success at Kalderos.

Lindsey describes the challenges facing remote workers who manage government-managed drug discount programs. As she explains, all drug discount stakeholders require novel technology-enabled collaboration tools.

To learn more, register for Kalderos’ panel discussion, The Dreaded Duplicate Discounts: Collaborating in the New Hybrid Working Landscape. You can also schedule a meeting with Kalderos at the Informa Connect Medicaid Drug Rebate Conference, October 13, 2022, in Chicago.

Read on for Lindsey’s insights.

Wednesday, September 21, 2022

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

The battle for control of the specialty patient continues.

In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs.

However, buy-and-bill appears to have rebounded substantially at hospitals. As I explain below, this resurgence likely reflects the success of vertically-integrated hospital/specialty pharmacy/physician mega-systems against the large insurer/PBM/specialty pharmacy/provider mega-organizations.

Read on for full details and the latest data.

FYI: The material in today’s article is adapted from Chapter 3 of our forthcoming 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, now available to preorder at special introductory pricing.

Tuesday, September 20, 2022

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 11, 2022, Drug Channels Institute will release The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our thirteenth edition— remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry.

We are providing you with the opportunity to preorder this thoroughly updated and revised 2022-23 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before October 11.


You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

Preorder and launch pricing discounts will be valid through October 21, 2022.

Friday, September 16, 2022

The Pulse of Electronic Benefit Verification Solutions: Know the Facts

Today’s guest post comes from Edward Hensley, Chief Commercial Officer at AssistRx.

Edward compares the pros and cons of electronic benefit verification using artificial intelligence, direct connectivity, or data connectivity. He also describes the circumstances where each solution provides the greatest value.

To learn more, download AssistRx’s free eBook: Specialty Drug Patient Support Programs: 2022 Progress Report.

Read on for Edward’s insights.

Wednesday, September 14, 2022

NEW: The Drug Channels 2023 Video Webinar Series

I invite you to join me for three new video webinars during 2023. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia.

During these events, I'll address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, company announcements, and more. I’ll share DCI’s latest market data to help you stay on top of new developments. You will be able to use these events as both a capstone of your current learning and a touchpoint for the future.

The three events are scheduled for 12:00 p.m. to 1:30 p.m. ET on the following dates:
  • March 31, 2023
  • June 23, 2023
  • December 15, 2023 (Drug Channels Outlook 2024)
For 2023, we are offering a new Corporate Pricing option that will allow larger organizations to register hundreds of colleagues for one fixed price.


Read on for my video invitation and full details on pricing, including substantial discounts for multiple sites.

Tuesday, September 13, 2022

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies

By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169).

Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements.

I can only barely scratch the surface in this article, so feel free to share your own thoughts in the comments below or on social media.

At this point in our country’s history, you might think Congress would have learned the immutable law of 730-page bills: Legislate in haste, repent at leisure.

Friday, September 09, 2022

Patients At Risk As Healthcare Navigates Affordability

Today’s guest post comes from Kristina Crockett, Vice President of Product Management at CoverMyMeds.

Kristina discusses the affordability challenges that patients face in our complex and confusing healthcare system. She then explains how data and technology can help payers, manufacturers, and providers improve medication access.

To learn more about CoverMyMeds’ comprehensive affordability solutions, download Overcoming Medication Affordability Challenges with Patient-Centered Solutions.

Read on for Kristina’s insights.

Wednesday, September 07, 2022

The Biosimilar Boom and the Coming Humira Price War (Video)

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. Prices are dropping while adoption accelerates. In many therapeutic areas, biosimilars’ market share is approaching 80%. In the video below, I review these developments and discuss lessons from the launch of Semglee, the first interchangeable insulin.

I also offer some thoughts on 2023 and 2024. That’s when Humira, the best-selling drug in the U.S., will face multiple biosimilar competitors. Some—but likely not all—of these products will have interchangeability with Humira.

The video is excerpted from last month’s Specialty Drugs Update: Trends, Controversies, and Outlook video webinar. During the webinar, I speculated that net prices in the Humira category will be 70% or more below today’s prices. If you missed the live event, you can register to watch a replay and download the full slide deck.

Despite these positive recent developments, the just-passed Inflation Reduction Act (IRA) seems likely to disrupt the biosimilar market by altering launch strategies. However, the IRA won’t affect the coming Humira price war.

Enjoy!

Friday, August 26, 2022

Your Brand Just Got Added to a Must-Have Formulary: Now What?

Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx.

Chris discusses the benefits of using in-electronic health record (EHR) messaging to communicate formulary information to both healthcare providers and patients during the patient encounter. Click here to learn more about ConnectiveRx’s in-EHR messaging

You can also register for Your Brand Just Got Added to a Must-Have Payer Formulary, Now What?, a free webinar on September 29th at 1:00 P.M. ET.

Read on for Chris’ insights.

Tuesday, August 23, 2022

Drug Channels News Roundup, August 2022: Gov. Dean vs. Maximizers, Cancer vs. Copays, Specialty Drug Trends, Biosimilar Transitivity, and Dr. G. vs. PBMs

Our news-laden summer is coming to an end. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline:
  • Howard Dean attacks patient-unfriendly cost shifting
  • Cancer patients’ views of copay assistance
  • My $0.02 on key specialty pharmacy trends
  • Evidence for biosimilar-to-biosimilar switching
Plus, Dr. Glaucomflecken takes on PBMs!

P.S. Join my more than 31,000 LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 15,000 followers.

Monday, August 22, 2022

Informa Connect’s Copay, Reimbursement and Access Congress

Informa Connect’s Copay, Reimbursement and Access Congress
Hybrid Event | October 12-14 in Philadelphia, PA
www.informaconnect.com/copay

Exclusive Offer: Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration

An important event for all aspects cost sharing, Copay, Reimbursement and Access Congress is back and better than ever! This year's event features a brand new look with the same great content, dedicated tracks, diverse and robust speaking faculty and greater networking opportunities. Now is the time to join to drive patient assistance, adherence and access forward—it’s all happening October 12-14.

Exclusive Offer: View the agenda and register today. Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration.

Why should you attend this pivotal event?

Copay and cost sharing programs are growing continuously more complex. The recent enforcement actions surrounding cost sharing programs are evidence that the shifting market dynamics remain a deep concern and bring about many questions for access professionals.

How are you managing out-of-pocket costs for patients? Do you have clarity on the further of health policy? What is the impact of accumulator and maximizer program utilization on your organization?

In just two-and-a-half days, walk away with answers to these questions and more from experts from across the industry. You would be remiss not to join seasoned leaders, your peers and leading solution providers as they navigate marketplace trends and dive into the impact coupons, accumulators, maximizers, benefit design, innovation and drug pricing legislation have on patient affordability and out-of-pocket costs and provide critical insights on industry standards, forward-thinking strategies to optimize copay and cost sharing programs to accelerate access and commercialization and so much more.

Can’t miss content highlights:
  • Two Pre-Conference Workshops
    • Copay 101 Workshop
    • Product Launch and Commercialization Summit
  • Marketplace Trends Opening Panel
  • Advocacy Insights and Furthering Access to Care
  • Government Enforcement Trends Impacting Copay Assistance
  • Analyze the Effect, Impact and Utilization of Accumulator and Maximizer Programs
  • And more!
PLUS! Two Dedicated Tracks for Your Focus Area:

Innovative Copay Program Design and Utilization Management
  • Implementing Innovation to Drive Next Generation Copay Design
  • Legal Implications and Compliance for Copay Programs
  • Utilizing Copay Data to Drive Program Decisions and Product
  • And more!
  • Reimbursement Strategies and Contracting
    • Value-Based Contracting Frameworks and Considerations
    • HEOR, RWE and Their Roles in Reimbursement
    • Rebates and Reimbursement—Breaking Down the Pricing Strategy
    • And more!
    Exclusive Offer: View the agenda and register today. Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration.

    Informa Connect will see you there!

    *Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.
    The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).

    Friday, August 19, 2022

    The Next Great Healthcare Surge: A ‘Diagnosis Explosion’

    Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds.

    John discusses how a patient-centric technology solution can increase access and affordability for patients. He goes on to describe how human contact and support helps patients understand their disease and their treatment plan, thus increasing adherence.

    Click here to learn how CoverMyMeds’ technology interventions help patients.

    Read on for John’s insights.

    Monday, August 15, 2022

    The 340B Program Climbed to $44 Billion in 2021—With Hospitals Grabbing Most of the Money

    Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! Even better, my Freedom of Information Act (FOIA) request was able to pry out detailed purchases by covered entity type.

    The data tell a familiar story. For 2021, discounted purchases under the 340B program reached a record $43.9 billion—an astonishing $5.9 billion (+15.6%) higher than its 2020 counterpart. Hospitals accounted for 87% of these skyrocketing 340B purchases.

    What’s more, the difference between list prices and discounted 340B purchases also grew, to $49.7 billion (+$7.0 billion). This figure approximates the money collected by 340B covered entities.

    340B advocates have been screaming that “drug companies are cutting 340B,” but the data tell a very different story. Only in the U.S. healthcare system can billions more in payments and spreads be considered a cut.

    Read on for full details and analysis, including the opportunity to download your very own copy of the raw data from HRSA.

    Friday, August 12, 2022

    Improving Out-of-Pocket Cost Transparency For Physicians

    Today’s guest post comes from Divya Iyer, VP, Strategy and Business Development, Pharma Manufacturer Solutions at GoodRx.

    Divya highlights new GoodRx research on the out-of-pocket cost gap between brand-name and generic prescriptions. She discusses the challenges that providers face when having real-time discussions with patients about out-of-pocket costs. Divya then explains how GoodRx partners with pharmaceutical companies to improve cost transparency and communication between patients and providers.

    Click here to learn more about how GoodRx helps brand teams engage providers in specific specialties.

    Read on for Divya’s insights.

    Tuesday, August 09, 2022

    Texas Shows Us Where PBMs’ Rebates Go

    Over the weekend, the U.S. Senate passed a massive overhaul of the Medicare Part D program. If passed into law, these changes will have many unintended consequences, but will not address the warped incentives baked into our current rebate system.

    This makes it a good time to review the murky, little-seen economics of how commercial plan sponsors and payers access the billions of dollars in manufacturer rebates and fee that are negotiated by their pharmacy benefit managers (PBMs).

    Our analyses of new Texas-mandated PBM disclosures reveal that plan sponsors receive most of the rebates, fees, and other payments from manufacturers. However, PBMs retain an unexpectedly large share of these payments—while the patients whose prescriptions generated these funds get almost nothing.

    In other words, plans spread around manufacturers’ rebates and fees to offset premiums for all beneficiaries, rather than lower out-of-pocket costs for drugs that plans buy at a discounted price. Perhaps Congress will someday get around to corralling these funds.

    Friday, August 05, 2022

    Three Technology Tactics for Overcoming Prior Authorization Hurdles

    Today’s guest post comes from Karina Castagna, SVP of Access and Adherence at OptimizeRx.

    Karina discusses the challenges health care providers and patients face in their quest to secure prior authorizations from payers. She argues that manufacturers adopt an electronic health record-based solution to facilitate access to therapies, from the point of prescription through the point of dispensing at the pharmacy.

    To test the efficacy of your market access digital strategy against industry best practices, take the OptimizeRx Market Access Strategy Quiz.

    Read on for Karina’s insights.

    Tuesday, August 02, 2022

    The Shady Business of Specialty Carve-Outs

    Watch out! Plan sponsors are getting even bolder in their attempts to grab financial support intended for patients. The latest scam is called a specialty carve-out.

    Here’s the game: A commercial plan eliminates coverage for all specialty drugs. Beneficiaries are then shunted over to a charitable foundation, because they are now disguised as uninsured—at least for specialty drugs. Naturally, the vendor skims a healthy share of the charity’s money.

    In addition to the ethical and compliance issues, some vendors raise safety risks by sourcing prescriptions from non-U.S. pharmacies as a backup.

    The Orwellian euphemism for this “benefit” design: alternative funding program.

    A new survey reveals that an astounding four out of 10 commercial plans are already using, or exploring the use of, these specialty carve-out programs. Yikes.

    Read on for an overview of these shady programs—and the many problems they are creating.

    Friday, July 29, 2022

    Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

    This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook .

    Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending.

    Click here to see the original post from April 2022.


    The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently released the latest projections for U.S. spending on healthcare. (See links below.) These data provide our first official look at post-pandemic U.S. healthcare spending.

    As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. healthcare spending. What’s more, taxpayers—via Medicare and Medicaid—will continue to crowd out the private insurance market. One bright spot: consumers will account for an ever-smaller share of drug spending.

    Thus, the government actuaries expect that pharmaceuticals will not be the key driver of U.S. healthcare spending growth. Will someone tell our elected officials?

    Thursday, July 28, 2022

    Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

    This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook .

    Click here to see the original post from May 2022.


    Time for Drug Channels’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below.

    When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs to less than half of their list prices.

    What’s more, average net drug prices have declined for the past five years—though a few companies had net price gains or slower declines in 2021.

    As I have pointed out many times, pharma industry perma-critics refuse to accept that brand-name drug prices are falling—or that prescription drug spending is a small and stable portion of overall U.S. healthcare expenditures. That’s why I refer to them as drug pricing flat earthers (#DPFE).

    As famous economist John Maynard Keynes reportedly said: “When the facts change, I change my mind.” What will the DPFEs do?

    Wednesday, July 27, 2022

    DCI’s Top 15 Specialty Pharmacies of 2021—And Three Factors That Will Reshape 2022 (rerun)

    This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook .

    One update to the list below: CVS Health has quietly purchased AmerisourceBergen's US Bioservices specialty pharmacy.

    Click here to see the original post from May 2022.


    In Drug Channels Institute’s list of the top 15 pharmacies of 2021, we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues.

    To complement that broader ranking, we present below our exclusive and updated list of the top 15 pharmacies based on specialty drug dispensing revenues in 2021. You will see that PBMs and insurers retained their dominance over specialty dispensing.

    But as I explain below, 2022 will be a year of transition. Significant volume will shift to the larger players, as Centene plots its exit, Walgreens’ specialty pharmacy business collapses, and manufacturers’ 340B contract pharmacy restrictions continue.

    This week, I’m attending Asembia’s Specialty Pharmacy Summit. In a future article, I’ll violate Vegas code and tell you what happened.

    Tuesday, July 26, 2022

    Warped Incentives Update: The Gross-to-Net Bubble Exceeded $200 Billion in 2021 (rerun)

    This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook .

    ICYMI, the unimplemented rule to reform rebates in Medicare Part D remains the ultimate budget gimmick. More than $122 billion in "savings" (offsets) from the current drug pricing reconciliation legislation comes from blocking rebate reform—which never even happened.

    Click here to see the original post from March 2022.


    Time for Drug Channels Institute’s annual update on the gross-to-net bubble—the ever-growing dollar gap between sales at brand-name drugs' list prices and their sales at net prices after rebates and other reductions.

    We estimate that the gross-to-net bubble reached $204 billion for patent-protected brand-name drugs in 2021. If we include brand-name drugs that have lost patent protection and face competition from generic equivalents, the bubble was even higher, at $236 billion.

    Pharmaceuticals are the only part of the U.S. healthcare system in which the difference between list and net prices is monetized as rebates and redistributed via intermediaries to payers. This bubble reflects—and drives—both patients’ affordability problems, intermediaries' warped incentives, and politicians’ misunderstandings of U.S. drug prices.

    Read on for our latest data—and a reminder why SpongeBob SquarePants remains a fixture on Drug Channels.

    Monday, July 25, 2022

    The Top Pharmacy Benefit Managers of 2021: The Big Get Even Bigger (rerun)

    This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook.

    Click here to see the original post from April 2022.


    The highly-consolidated PBM market notched another year of increased concentration.

    Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. For 2021, we estimate that the three biggest PBMs accounted for 80% of total equivalent prescription claims. Significant business relationships among the largest companies continue to shift market share.

    As I explain below, the prospects for market disruption remain low, so the controversial warped incentives of the rebate system will continue to distort the drug channel.

    Friday, July 22, 2022

    The New Hub Features Improving Patient Assistance

    Today’s guest post comes from Ian Ocilka, Senior VP of Client Solutions at ConnectiveRx.

    Ian shares an overview of The Evolving Role of Hubs and Patient Services, his recent presentation at Informa Connect's Hub and Specialty Model East conference in June.

    Click here to watch Ian’s full presentation.

    Read on for Ian’s insights.

    Wednesday, July 20, 2022

    Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

    Cut through the steamy summer haze with our refreshing selection of articles and insights. In this issue:
    • CVS disassociates itself from its chain pharmacy association
    • Payers are paying attention to ICER
    • Benefits of the biosimilar boom
    • A fantastic takedown of health insurance deductibles
    Plus, I join the Advisory Board of Alto Pharmacy.

    P.S. Join my nearly 30,000 (!) LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter, where I have more than 14,700 followers.

    Join me next week for my new live video webinar, Specialty Drugs Update: Trends, Controversies, and Outlook, on July 29, 2022, from 12:00 p.m. to 1:30 p.m. ET. I’ll cover market trends, payer strategies, channel developments, key trends that will help you plan for the future, and more. Click here for details and registration info.

    Monday, July 18, 2022

    Informa Connect’s Medicaid Drug Rebate Program (MDRP) Summit

    Informa Connect’s Medicaid Drug Rebate Program (MDRP) Summit
    Hybrid Event
    October 12-14, 2022 | Chicago, IL
    www.informaconnect.com/MDRP

    Don’t miss the Medicaid Drug Rebate Program Summit coming up this fall in Chicago (or virtually). You'll return to the office having mastered complex regulatory guidelines to deliver compliant government pricing and reporting programs. MDRP 2022 is your chance to hear directly from the government regulators creating the rules, the industry leaders interpreting them and the manufacturer experts implementing them – You won’t want to miss it!

    View the agenda to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/MDRP for further details and to register. Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to August 12, 2022.*

    MDRP Agenda Highlights Include:
    • Congressional Insights from the Senior Health Advisor to the Senate Committee on Finance
    • Examination of the 30 Year History of 340B, with current insights into the latest litigation
    • Coverage on FSS Refresh and Life Cycle, PLUS sessions on other federal, state and local contracting agreements that you may be missing
    • Insights into Patient Support and Patient Assistance Programs and how they affect you
    • Updates on all the implications of recent rules and proposed regulations
    • Strategies for Emerging, Small and Mid-Size companies
    • Back by Popular Demand: Government Pricing and Reporting 101 Workshop, State Dispute Meetings and the Town Hall with States and Manufacturers, and the Half-day Workshop which includes the State-by-State review of legal requirements and operational challenges for State Drug Price Reporting and Transparency
    • Perspectives from 60+ experts, representing companies such as Apexus, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Chiesi USA, CSL Behring, Deciphera Pharmaceuticals, Gainwell Technologies, Genentech, Gilead, Mallinckrodt, Novartis, Pfizer, Regeneron, United Therapeutics, Vifor Pharma and more!
    • And so much more!
    PLUS! The 2022 Summit features a Closed-Door Interactive Executive Strategy Session which is limited to 40 participants. If interested in attending, email Danica Schroth for further details!

    Don’t miss the chance to conquer the complex, ever-evolving regulatory guidelines and accelerate your career by sourcing world-class content and everyone who matters in Medicaid.

    View the agenda to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/MDRP for further details and to register. Drug Channels readers will save 10% off when they use code 22DRCH10 and register prior to August 12, 2022.*

    *Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.


    The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).


    Friday, July 15, 2022

    What Manufacturers Need to Know About Alternative Payment Models

    Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT.

    Carolyn explains the advantages of alternative payment models (APM) for measuring and rewarding value and outcomes in our healthcare system. For more on how APMs measure value, click here to learn about MMIT’s Pulse Analytics Solution.

    Read on for Carolyn’s insights.